Literature DB >> 207297

Preparation and characterization of an antiserum to cultured human oat-cell carcinoma cells.

C E Newman, C H Ford, E Parkes.   

Abstract

Viable cultured oat-cell carcinoma cells were used to immunize a goat. The resulting antiserum contained high titres of anti-normal activity and antibodies to CEA. It was also shown, by indirect immunofluorescence, using fluorescein-conjugated rabbit anti-goat Ig, to localize at high titres on the surface membranes of human lung cancer cells of 4 different histological types. Booster immunizations produced a maximum secondary response one week after 2 weekly injections. The course of each immunization has been monitored for activity against normal human tissues, and the final sera have been absorbed with human spleen cells to remove anti-normal activity. Cross-reactivity with the lung-cancer-cell panel and antibodies to CEA persisted in high titre after absorption of anti-normal antibodies, and were present in the ammonium-sulphate-precipitated globulin fraction. The cells used for immunization did not produce detectable amounts of CEA in culture, and were not known to contain CEA prior to this experiment. Removal of anti-CEA antibodies by absorption with purified CEA has not reduced the cross-reactivity of the absorbed antiserum with the panel of human lung-cancer cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 207297      PMCID: PMC2009627          DOI: 10.1038/bjc.1978.116

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Immunochemotherapy of human malignant melanoma with chlorambucil-carrying antibody.

Authors:  T Ghose; S T Norvell; A Guclu; A S Macdonald
Journal:  Eur J Cancer       Date:  1975-05       Impact factor: 9.162

2.  Solubilization of an antigen associated with certain bronchial tumours.

Authors:  D Viza; M Louvier; J Phillips; C Boucheix; R A Guerin
Journal:  Eur J Cancer       Date:  1975-11       Impact factor: 9.162

3.  Carcinoembryonic antigen in patients with carcinoma of the lung.

Authors:  R G Vincent; T M Chu
Journal:  J Thorac Cardiovasc Surg       Date:  1973-08       Impact factor: 5.209

4.  A simple micro cytotoxicity test.

Authors:  D B Amos; H Bashir; W Boyle; M MacQueen; A Tiilikainen
Journal:  Transplantation       Date:  1969-03       Impact factor: 4.939

5.  Treatment of melanoma by passive humoral immunotherapy using antibody drug synergism.

Authors:  K D Everall; P Dowd; D A Davies; G J O'Neill; G F Rowland
Journal:  Lancet       Date:  1977-05-21       Impact factor: 79.321

6.  Roôle of carcinoembryonic antigen in bronchial carcinoma.

Authors:  C H Ford; C E Newman; J Lakin
Journal:  Thorax       Date:  1977-10       Impact factor: 9.139

7.  A plasma membrane antigen highly associated with oat-cell carcinoma of the lung and undetectable in normal adult tissue.

Authors:  C E Bell; S Seetharam
Journal:  Int J Cancer       Date:  1976-11-15       Impact factor: 7.396

8.  Antibody-drug synergism: An assessment of specific passive immunotherapy in bronchial carcinoma.

Authors:  C E Newman; C H Ford
Journal:  Lancet       Date:  1977-07-23       Impact factor: 79.321

9.  Extraction and preliminary characterization of a human bronchogenic carcinoma antigen.

Authors:  M J Frost; G T Rogers; K D Bagshawe
Journal:  Br J Cancer       Date:  1975-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.